• home
  • > Promotion Center >
  • News

새소식 차메디텍의 새로운 소식을 전달하고 있습니다.

CHA Bio&Diostech conducts Korea’s first human clinical trial using embryonic stem cells to treat retina degeneration.
Date 2013-11-04 Hit 4692

CHABio&Diostech conducts Korea’s first human clinical trial using embryonic stem cells to treat dry type age related macular dystrophy (dry AMD)

- Announced the result of cell therapy product transplant on two stargardt’s macular dystrophy patients and two macular degeneration patients
- Observed improvement of visual functions and could not find any adverse effect until now.

CHA Bio&Diostech announces early stage of Korea’s first clinical trial on the treatment of stargardt’s macular dystrophy (SMD) and mascular degeneration using human embryonic stem cells (hESCs). The surgery was performed at the Bundang CHA Hospital in Korea by a team of surgeons in the department of ophthalmology led by Professor Won Kyung Song.
CHA Bio&Diostech has recruited two dry age-related macular degeneration (dry AMD) patients and two Stargardt’s macular dystrophy (SMD) patients for its clinical trial. These patients were transplanted with embryonic stem cell derived retinal epithelial cell. Adverse effects were not found and improvement of visual functions was observed. Patients who could read only one word on the ETDRS standard were improved to see 7 words after the treatment.

Representative of CHABio&Diostech, Won S. Yang has mentioned that they will recruit one more stargardt’s macular dystrophy (SMD) patient and 10 more macular degeneration patients as the early stage of clinical trials has shown positive results.

Currently, CHABio&Diostech is recruiting Stargardt’s macular dystrophy (SMD) patients for clinical trials and recently received a certification of its clinical trial from the KFDA.

Forward-Looking Statements
Certain statements contained herein constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “anticipates”, “plans”,  “estimates”, “expects” and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors such as changes in market conditions and strategy revisions. The company does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.

Previous CHABio&Diostech signs an exclusive licensing contract with placental stem cell therapy product development company, ‘Pluristem’